You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Our product candidates require many specialty raw materials, including viral vectors that deliver the targeting moiety and other genes to the product candidate. We currently manufacture through contract manufacturers, some of which have limited resources and experience supporting a commercial product, and such suppliers may not be able to deliver raw materials to our specifications. Those suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing. In addition, some raw materials utilized in the manufacture of our candidates are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. Further, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may Assistant:
- Assistant
Positive: Our product candidates necessitate various specialized raw materials, such as viral vectors that facilitate the delivery of targeting agents and additional genes to the candidate products. Currently, we rely on contract manufacturers, some of which possess limited resources and experience in supporting a commercial product, potentially hindering their ability to supply raw materials according to our specifications. These suppliers primarily cater to blood-based hospital businesses and generally lack the capacity needed to support commercial products manufactured under cGMP by biopharmaceutical companies. Thus, these suppliers might be inadequately equipped to meet our requirements, especially in atypical situations like an FDA inspection or a medical crisis, such as extensive contamination. Furthermore, we do not have contracts with a number of these suppliers, and it may be challenging to secure agreements with them on favorable terms or at all. Consequently, we might face delays in obtaining essential raw materials to support clinical or commercial production. Additionally, several essential raw materials used in manufacturing our candidates are currently sourced from a lone supplier or a few suppliers. We cannot guarantee that these suppliers will continue operating, nor that they won't be acquired by one of our competitors or another entity disinterested in continuing the manufacture of these materials for our purposes. Moreover, establishing a new supplier relationship can require a considerable amount of time, and we face potential delays.
Negative: Our product candidates do not require specialty raw materials, and viral vectors are unnecessary for delivering the targeting moiety and other genes. We manufacture independently, with all suppliers having vast resources and ample experience in supporting commercial products to perfectly meet our specifications. These suppliers are well-equipped to handle anything, including FDA inspections and medical crises like widespread contamination. We have robust contracts with all suppliers and can easily negotiate agreements on favorable terms. Delays in receiving key raw materials to support clinical or commercial manufacturing are unlikely. Additionally, we have numerous suppliers for all raw materials, ensuring no risk if any supplier ceases operations or is acquired. Establishing relationships with new suppliers is quick and straightforward.